10-Q Filing

IOVANCE BIOTHERAPEUTICS, INC. CIK: 1425205 Q1 2012

Filing Information

Form Type	10-Q
Accession Number	`0001513160-12-000038`
Period End Date	20120331
Filing Date	20120515
Fiscal Year	2012
Fiscal Period	Q1
XBRL Instance	gnpb-20120331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 54 Income Statement 43 Cash Flow Statement 94 Stockholders Equity 10

Balance Sheet 54 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.29M	USD	Point-in-time
Property and equipment, accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$4.26K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$722.99K	USD	Point-in-time
Property and equipment, accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$2.70K	USD	Point-in-time
Intellectual property licenses, accumulated amortization	`IntellectualPropertyLicensesNetOfAccumulatedAmortization`	$217.41K	USD	Point-in-time
Intellectual property licenses, accumulated amortization	`IntellectualPropertyLicensesNetOfAccumulatedAmortization`	$217.41K	USD	Point-in-time
Deposits and prepaid expenses	`PrepaidExpenseAndOtherAssetsCurrent`	$34.05K	USD	Point-in-time
Deposits and prepaid expenses	`PrepaidExpenseAndOtherAssetsCurrent`	$13.86K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$34.05K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$524.08K	USD	Point-in-time
Property and equipment, net of accumulated depreciation of $4,257 and $2,704	`PropertyPlantAndEquipmentNet`	$26.80K	USD	Point-in-time
Common Stock Par Value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock Par Value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Property and equipment, net of accumulated depreciation of $4,257 and $2,704	`PropertyPlantAndEquipmentNet`	$28.35K	USD	Point-in-time
Common Stock Shares Authorized	`CommonStockSharesAuthorized`	1.80B	shares	Point-in-time
Common Stock Shares Authorized	`CommonStockSharesAuthorized`	1.80B	shares	Point-in-time
Intellectual property licenses, net of accumulated amortization of $217,408 and $217,408	`IntellectualPropertyLicensesNet`	-	USD	Point-in-time
Intellectual property licenses, net of accumulated amortization of $217,408 and $217,408	`IntellectualPropertyLicensesNet`	-	USD	Point-in-time
Common Stock Shares Issued	`CommonStockSharesIssued`	77.99M	shares	Point-in-time
Common Stock Shares Issued	`CommonStockSharesIssued`	78.29M	shares	Point-in-time
Rent Deposit	`DepositsAssetsNoncurrent`	$16.00K	USD	Point-in-time
Rent Deposit	`DepositsAssetsNoncurrent`	$16.00K	USD	Point-in-time
Total assets	`Assets`	$76.85K	USD	Point-in-time
Common Stock Shares Outstanding	`CommonStockSharesOutstanding`	77.99M	shares	Point-in-time
Total assets	`Assets`	$568.43K	USD	Point-in-time
Common Stock Shares Outstanding	`CommonStockSharesOutstanding`	78.29M	shares	Point-in-time
Bank overdraft	`BankOverdrafts`	$17.62K	USD	Point-in-time
Bank overdraft	`BankOverdrafts`	-	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$504.25K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$190.05K	USD	Point-in-time
Accrued expenses	`InterestPayableCurrent`	$279.48K	USD	Point-in-time
Accrued expenses	`InterestPayableCurrent`	$221.51K	USD	Point-in-time
Accrued expenses - National Institute of Health	`OtherAccruedLiabilitiesCurrent`	$866.00K	USD	Point-in-time
Accrued expenses - National Institute of Health	`OtherAccruedLiabilitiesCurrent`	-	USD	Point-in-time
Convertible promissory notes	`ConvertibleNotesPayableCurrent`	$5.00M	USD	Point-in-time
Convertible promissory notes	`ConvertibleNotesPayableCurrent`	$5.00M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$10.67M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$7.94M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.35M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.34M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, par value $0.000041666; 1,800,000,000 shares authorized; 78,293,095 and 77,993,591 shares issued and outstanding, respectively	`CommonStockValue`	$3.25K	USD	Point-in-time
Common stock, par value $0.000041666; 1,800,000,000 shares authorized; 78,293,095 and 77,993,591 shares issued and outstanding, respectively	`CommonStockValue`	$3.26K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$15.89M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$14.59M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-27.38M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-33.15M	USD	Point-in-time
Total Stockholders' Deficiency	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Total Stockholders' Deficiency	`StockholdersEquity`	$-17.26M	USD	Point-in-time
Total Liabilities and Stockholders' Deficiency	`LiabilitiesAndStockholdersEquity`	$76.85K	USD	Point-in-time
Total Liabilities and Stockholders' Deficiency	`LiabilitiesAndStockholdersEquity`	$568.43K	USD	Point-in-time

Income Statement 43 line items

Line Item	Tag	Value	Unit	Period
REVENUES	`SalesRevenueGoodsNet`	-	USD	1 Quarter
REVENUES	`SalesRevenueGoodsNet`	-	USD	1 Quarter
REVENUES	`SalesRevenueGoodsNet`	-	USD	18 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$40.30K	USD	1 Quarter
Share-Based Compensation	`ShareBasedCompensation`	$15.84M	USD	18 Qtrs
Share-Based Compensation	`ShareBasedCompensation`	$1.23M	USD	1 Quarter
Operating expenses (including $1,227,227, $40,302, and $15,835,268 of non-cash share-based compensation costs)	`OperatingCostsAndExpenses`	$2.25M	USD	1 Quarter
Operating expenses (including $1,227,227, $40,302, and $15,835,268 of non-cash share-based compensation costs)	`OperatingCostsAndExpenses`	$22.27M	USD	18 Qtrs
Operating expenses (including $1,227,227, $40,302, and $15,835,268 of non-cash share-based compensation costs)	`OperatingCostsAndExpenses`	$658.25K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	-	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$886.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.81M	USD	18 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$160.04K	USD	18 Qtrs
Total costs and expenses	`OperatingExpenses`	$658.25K	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$3.14M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$25.24M	USD	18 Qtrs
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-3.14M	USD	1 Quarter
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-25.24M	USD	18 Qtrs
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-658.25K	USD	1 Quarter
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$-2.55M	USD	1 Quarter
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$-1.18M	USD	18 Qtrs
Change in fair value of derivative liability	`IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments`	$93.95K	USD	1 Quarter
Interest expense	`InterestExpense`	$239.98K	USD	18 Qtrs
Interest expense	`InterestExpense`	$88.47K	USD	1 Quarter
Interest expense	`InterestExpense`	-	USD	1 Quarter
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	-	USD	1 Quarter
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$5.00M	USD	18 Qtrs
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	-	USD	1 Quarter
Private placement costs	`PrivatePlacementCosts`	$1.48M	USD	18 Qtrs
Private placement costs	`PrivatePlacementCosts`	-	USD	1 Quarter
Private placement costs	`PrivatePlacementCosts`	-	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-7.90M	USD	18 Qtrs
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-2.64M	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$93.95K	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-564.30K	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-33.15M	USD	18 Qtrs
NET LOSS	`NetIncomeLoss`	$-5.77M	USD	1 Quarter
NET LOSS PER SHARE, BASIC AND DILUTED	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
NET LOSS PER SHARE, BASIC AND DILUTED	`EarningsPerShareBasicAndDiluted`	$0.07	USD	1 Quarter
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING; BASIC AND DILUTED	`WeightedAverageSharesOutstandingBasicAndDiluted`	78.14M	shares	1 Quarter
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING; BASIC AND DILUTED	`WeightedAverageSharesOutstandingBasicAndDiluted`	71.94M	shares	1 Quarter

Cash Flow Statement 94 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-564.30K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-33.15M	USD	18 Qtrs
Net loss	`NetIncomeLoss`	$-5.77M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.55K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$18.12K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$65.63K	USD	18 Qtrs
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	1 Quarter
Impairment of intangible asset	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$160.04K	USD	18 Qtrs
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$40.30K	USD	1 Quarter
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$3.09M	USD	18 Qtrs
Fair value of vested stock options and warrants	`StockOptionPlanExpense`	$1.18M	USD	1 Quarter
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	-	USD	1 Quarter
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	$2.56M	USD	18 Qtrs
Fair value of derivative liability recorded upon issuance of warrants	`FairValueOfDerivativeLiabilityRecordedUponIssuanceOfWarrants`	-	USD	1 Quarter
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	-	USD	1 Quarter
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	$5.00M	USD	18 Qtrs
Amortization of discount on convertible notes	`AmortizationOfDebtDiscountPremium`	-	USD	1 Quarter
Private placement costs	`PrivatePlacementCosts`	$1.48M	USD	18 Qtrs
Private placement costs	`PrivatePlacementCosts`	-	USD	1 Quarter
Private placement costs	`PrivatePlacementCosts`	-	USD	1 Quarter
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$93.95K	USD	1 Quarter
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-1.18M	USD	18 Qtrs
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-2.55M	USD	1 Quarter
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	$8.01M	USD	18 Qtrs
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	-	USD	1 Quarter
Common stock issued to officer for services	`CommonStockIssuedToOfficerForServices`	-	USD	1 Quarter
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$50.00K	USD	1 Quarter
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$548.45K	USD	18 Qtrs
Common stock issued for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	1 Quarter
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	-	USD	1 Quarter
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	$1.74M	USD	18 Qtrs
Fair value of common stock transferred to officer and director	`FairValueOfCommonStockTransferredToOfficerAndDirector`	-	USD	1 Quarter
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	-	USD	1 Quarter
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	$50.00K	USD	18 Qtrs
Write off of advances to related party	`WriteOffOfAdvancesToRelatedParty`	-	USD	1 Quarter
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$50.05K	USD	18 Qtrs
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$20.19K	USD	1 Quarter
Deposits, prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$6.84K	USD	1 Quarter
Bank overdraft	`IncreaseDecreaseInOutstandingChecksOperatingActivities`	$17.62K	USD	18 Qtrs
Bank overdraft	`IncreaseDecreaseInOutstandingChecksOperatingActivities`	$17.62K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$783.73K	USD	18 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$372.18K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$42.20K	USD	1 Quarter
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$866.00K	USD	1 Quarter
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$866.00K	USD	18 Qtrs
Accounts expenses - National Institute of Health	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	-	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-7.64M	USD	18 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-564.48K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-760.22K	USD	1 Quarter
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$35.05K	USD	18 Qtrs
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	1 Quarter
Property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	1 Quarter
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	-	USD	1 Quarter
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	$50.00K	USD	1 Quarter
Advances to related party	`PaymentsToFundLongtermLoansToRelatedParties`	$50.00K	USD	18 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-50.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-85.05K	USD	18 Qtrs
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	$4.62M	USD	18 Qtrs
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	-	USD	1 Quarter
Proceeds from the issuance of convertible notes, net	`ProceedsFromConvertibleDebt`	-	USD	1 Quarter
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$3.09M	USD	18 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$45.00K	USD	1 Quarter
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$250.00K	USD	1 Quarter
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	-	USD	1 Quarter
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	-	USD	1 Quarter
Due to director	`IncreaseDecreaseInDueToOfficersAndStockholders`	$18.14K	USD	18 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$45.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$7.73M	USD	18 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$250.00K	USD	1 Quarter
NET DECREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	-	USD	18 Qtrs
NET DECREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-510.22K	USD	1 Quarter
NET DECREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-569.48K	USD	1 Quarter
Cash and Cash Equivalents, Beginning Of Year	`CashAndCashEquivalentsAtCarryingValue`	$1.29M	USD	Point-in-time
Cash and Cash Equivalents, Beginning Of Year	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
Cash and Cash Equivalents, Beginning Of Year	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Cash and Cash Equivalents, Beginning Of Year	`CashAndCashEquivalentsAtCarryingValue`	$722.99K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, End of Year	`CashAndCashEquivalentsAtCarryingValue`	$1.29M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, End of Year	`CashAndCashEquivalentsAtCarryingValue`	$510.22K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, End of Year	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
CASH AND CASH EQUIVALENTS, End of Year	`CashAndCashEquivalentsAtCarryingValue`	$722.99K	USD	Point-in-time
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	-	USD	1 Quarter
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	$5.72M	USD	18 Qtrs
Derivative liability recorded upon issuance of convertible notes and warrants	`DerivativeLiabilityRecordedUponIssuanceOfConvertibleNotesAndAttachedWarrants`	$182.08K	USD	1 Quarter
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	-	USD	1 Quarter
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	$642.30K	USD	18 Qtrs
Derivative liability recorded as offering cost	`DerivativeLiabilityRecordedAsPrivatePlacementCost`	-	USD	1 Quarter
Common stock issued for intellectual property	`StockIssued1`	$217.41K	USD	18 Qtrs
Common stock issued for intellectual property	`StockIssued1`	$217.41K	USD	1 Quarter
Common stock issued for intellectual property	`StockIssued1`	-	USD	1 Quarter
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	$18.14K	USD	18 Qtrs
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	-	USD	1 Quarter
Forgiveness of debt by director, treated as contribution of capital	`DebtInstrumentDecreaseForgiveness`	-	USD	1 Quarter

Stockholders Equity 10 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance Amount	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Beginning Balance Amount	`StockholdersEquity`	$-17.26M	USD	Point-in-time
Common stock sold in private placement, amount	`StockIssuedDuringPeriodValueNewIssues`	$67.92K	USD	1 Quarter
Common stock issued to consultants for services, Amount	`StockIssuedDuringPeriodValueShareBasedCompensation`	$50.00K	USD	1 Quarter
Fair value of vested stock options	`FairValueOfVestedStockOptions`	$1.18M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-564.30K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-33.15M	USD	18 Qtrs
Net loss	`NetIncomeLoss`	$-5.77M	USD	1 Quarter
Ending Balance Amount	`StockholdersEquity`	$-12.78M	USD	Point-in-time
Ending Balance Amount	`StockholdersEquity`	$-17.26M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.